Business Wire

Alveo Technologies Announces New Executive Leadership, Open Platform Strategy


Alveo Technologies, Inc. (Alveo) today announced the appointment of three life sciences industry leaders to its senior executive team to advance the development of its novel molecular sensing and diagnostics technology and lead the company through strategic growth and commercialization of its rapid, multiplexed molecular diagnostic platform, be.well™. The company, seeking to catalyze broader adoption of its highly differentiated platform, is actively seeking collaborators to rapidly expand the menu of assays available within healthcare and beyond.

The innovative be.well™ platform, a prior X-Prize winner, pairs advanced molecular assays with secure, HIPAA- and GDPR-compliant cloud-enabled data analytics for real-time disease, pathogen and contaminant diagnoses, detection, and analysis. Designed to bring molecular sensing and diagnostics closer to the point of need, whether at the point of care, over the counter, at home, or in the field, the rapid, handheld and portable be.well™ platform can be customized to detect a wide range of diseases including COVID-19, Influenza A/B, and RSV, sexually transmitted infections and urinary tract infections as well as applications for veterinary, agricultural, and other industrial markets where low cost, accurate, rapid molecular testing, sampling, or detection capabilities are needed.

New Executive Leadership to Ensure Universal Access to Groundbreaking Technology

Shaun Holt, Chief Executive Officer, and Chairman of the Board of Directors

Shaun Holt serves as Chairman of the Board and Chief Executive Officer of Alveo Technologies. Previously, Shaun served as Chief Operating Officer of Atonarp, Inc., a Celesta Capital-backed optical- and mass-spectrometry instrumentation company. Prior to Atonarp, as Chief Financial Officer for Berkeley Lights, Inc., Shaun led the digital cell biology company through its $205 million initial public offering. In addition, Shaun held numerous finance leadership positions during his seven-year tenure at Illumina throughout its exponential growth phase. He brings more than 20 years of operational and financial leadership experience across various technology and life sciences companies from start-ups to large-capitalization companies. Shaun is an advisor to Celesta Capital and serves on the Board of Directors of Prellis Biologics.

Erik Tyrrell-Knott, Chief Business and Strategy Officer

As Alveo’s Chief Business and Strategy Officer, Erik Tyrrell-Knott leads business and market development, sales, partnering, and product management efforts, driving the Company’s commercial, partnership, and go-to-market strategies. With more than 20 years of experience in strategic business development for medical device and diagnostic companies ranging from start-ups to mature global corporations, Erik most recently served as Vice President of Business Development at Atonarp, Inc., and previously as Head of Business Development for Thermo Fisher Scientific, and previously as Senior Vice President of Business Development and Product Management at Mesa Biotech prior to its acquisition by Thermo Fisher.

Slava Elagin, PhD, MBA, Chief Technology Officer

Dr. Slava Elagin brings to Alveo more than 20 years of experience in the in vitro diagnostics and medical devices industries. Previously, Slava held senior executive operations and research and development positions with publicly traded and private companies including MiraVista Diagnostics, Meridian Biosciences, EraGen Biosciences, and Third Wave Technologies. He has led 15 molecular diagnostic product development projects from product concept through U.S. Food & Drug Administration clearances and commercialization and is the author on 12 U.S. patents and three global patents for molecular assays and diagnostics.

Proprietary Advanced Molecular Sensing Technology Offers Distinct Advantages

Alveo is leading the transformation of the point-of-need molecular sensing and health tech markets with an “open platform” approach to co-developing rapid molecular testing capabilities with collaborative partners across multiple markets.

“Alveo has spent seven years and more than $70 million dollars developing a bulletproof, mobile “Molecular Lab” that can deliver exquisitely sensitive and specific testing wherever, whenever it is needed: literally in the field for crop testing, on farms for animal testing, and most importantly in labs, pharmacies, and doctors’ offices for various infectious diseases,” says CEO Shaun Holt. “The future of healthcare, and molecular sensors as a whole, lies closer and closer to the patient or point of need, and the multiplexed Alveo platform will deliver insight and guidance with zero compromise.”

The be.well™ platform is the only point-of-care diagnostic platform available today that utilizes Alveo’s proprietary and globally patented method for the direct electrical sensing of nucleic acid amplification. This technology eliminates the need for specialized lighting and expensive optical detectors, while also simplifying certain aspects of primer manufacturing, providing a more robust and reliable diagnostic instrument.

Alveo’s platform can be used with various specimen types, such as nasal, blood, or urine samples, which eliminates the need to modify the platform design for different disease applications. The design architecture -- with a total of 15 components -- is reusable and rechargeable, Bluetooth- and cloud-enabled, with no moving parts or hazardous waste, is environmentally friendly, reduces manufacturing costs and limits supply chain risk. The simplicity of the detection methodology, its lower cost compared to other single-use diagnostic tests, and its wide range of health and disease applications are key advantages driving Alveo’s commercialization partnerships.

“A seminal pillar of Alveo’s growth is to open our platform to companies with expertise, market reach, and customer insights that extend beyond what Alveo can accomplish on our own,” says Erik Tyrrell-Knott. “Collaborating with partners to take molecular testing out of the lab, into new markets, and deliver actionable insights at the point of need is our core focus. The doors are open, and we are ready to co-develop.”

Alveo’s be.well™ COVID-19 Test received CE (Conformité Européene) Mark regulatory approval and the company is initially scaling up production for commercialization in the United Kingdom and European Union. Alveo is also actively pursuing 510(K) clearance from the U.S. Food and Drug Administration.

About Alveo

At Alveo we understand the importance of access to cutting-edge molecular testing and cloud-based data analytics for rapid diagnosis and management of infectious diseases. With an initial focus on acute respiratory infections including COVID-19, Flu A/B and RSV, Alveo’s agile and dynamic molecular diagnostic platform, be.well™, can be adapted to detect a wide range of diseases, bacteria, and other pathogens that threaten public health, across all modalities. We believe increased access to real-time test results will transform the way individuals, healthcare providers and public health professionals identify and manage infectious diseases. With be.well™, we will Know Sooner, Act Faster™.

To learn more, visit

To view this piece of content from, please give your consent at the top of this page.

Contact information

Staci Vernick for Alveo Technologies, Inc.
SL Vernick Communications

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Dentalis Animal Health appoints Advisory Board4.2.2023 15:09:00 CET | Press release

Dentalis Animal Health, a company specializing in Oral Health care for companion animals, has announced the appointment of its Advisory Board. Michael Kelly Michael Kelly is an Animal Health Pharmaceutical Industry veteran with broad international business experience. A graduate of Harvard Business School and Cornell University, Michael was hired by Ciba-Geigy to begin his post graduate career in Switzerland. Eventually ending up in the Novartis Animal Health US Division (following the Ciba-Sandoz merger) he rose to CFO and VP of North America. In 2009 Kelly joined Piedmont Animal Health (PAH), a drug development company, and served various roles including CFO, COO and President. During his tenure at PAH the organization received more FDA Companion Animal Drug approvals than any other Company in the Industry. Dr Stephanie Livermore Dr. Stephanie Livermore has been practicing companion animal medicine and surgery since her graduation from the University of Guelph in 2008. Dr. Livermore

Autel Brings MaxiCharger DC Compact to eCarExpo and Signs Partnership Agreement with Leading Charging Operator Eways4.2.2023 09:00:00 CET | Press release

Autel, a leading provider of automotive electronics and diagnostic equipment and tools, exhibited for the first time at eCarExpo, the largest electric vehicles fair in the Nordic countries, on February 3-5, 2023, in Friends Arena, Stockholm. Autel brought its portfolio of products featuring the recently launched electric vehicle charger the MaxiCharger DC Compact. This press release features multimedia. View the full release here: Autel signs partnership agreement with leading charging operator Eways (Photo: Business Wire) As Autel's newly launched DC charger for EVs, the MaxiCharger DC Compact is not only sleek and compact with a 21.5-inch LCD touchscreen, but also powerful enough to provide up to 47kW of power for the European version. Either placed on a pedestal, or set on wheels for ultimate portability, the MaxiCharger DC Compact is perfect for charging operators wanting to provide their customers with a quick charge option

U.S. FDA Approves Takeda’s TAKHZYRO ® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older4.2.2023 00:48:00 CET | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expanded use of TAKHZYRO® (lanadelumab-flyo) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in pediatric patients 2 to <12 years of age.1 Prior to today’s approval, the only approved routine prophylaxis treatment options for children 6 to <12 years of age required dosing every three to four days,and children with HAE 2 to <6 years of age had no approved prophylaxis treatment, making TAKHZYRO the first prophylaxis treatment for this age group.1-5 The recommended dose is 150 mg/1 mL solution in a single-dose prefilled syringe every four weeks in patients 2 to <6 years of age and every two weeks in patients 6 to <12 years of age.1 HAE attacks can involve serious and debilitating swelling in the abdomen, face, feet, genitals, hands and throat.5,7 Potentially fatal upper airway angioedema has been reported i

SLB Completes Acquisition of Gyrodata Incorporated3.2.2023 22:05:00 CET | Press release

SLB (NYSE: SLB) today announced it has completed the acquisition of Gyrodata Incorporated, a global company specializing in gyroscopic wellbore positioning and survey technology. The transaction will incorporate Gyrodata’s wellbore placement and surveying technologies within SLB’s Well Construction business, bringing customers innovative drilling solutions. This combination will improve wellbore quality and reduce drilling risk to unlock even the most remote and complex reservoirs. Integrating three-axis solid state gyro measurements with the latest SLB technological innovations will help ensure tighter trajectory control, reduce data acquisition time and improve the decision-making process—resulting in greater overall drilling efficiency. “I’m excited for this historic moment that will bring innovative solutions to the SLB Well Construction division and our industry,” said Jesus Lamas, president, Well Construction, SLB. “The technology-driven acquisition of Gyrodata is aligned with SL

Gallagher Re Joins ABIR and EY as 2023 Bermuda Risk Summit Headline Sponsors3.2.2023 16:17:00 CET | Press release

The Bermuda Business Development Agency (BDA) is pleased to announce that Gallagher Re has joined the Association of Bermuda Insurers and Reinsurers (ABIR) and EY as headline sponsors of the second annual Bermuda Risk Summit. Adam Schwebach, Executive Vice President, Gallagher Re, said, “Gallagher Re is proud to support the second Bermuda Risk Summit, an annual event that showcases the breadth and versatility of Bermuda’s globally significant risk market. This event serves as a timely opportunity to connect with industry leaders ahead of midyear renewals and we applaud the BDA for their efforts in making the Bermuda Risk Summit a success.” David Hart, BDA CEO, said, “We are just so excited to welcome Gallagher Re as our third and final headline sponsor, along with ABIR and EY. The theme of the 2023 Bermuda Risk Summit, being held from March 6-8, 2023, at the Hamilton Princess & Beach Club is ‘Innovation, Sustainability and Collaboration. We anticipate an even stronger attendance level